DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06865365

Not yet recruitingPhase 4

Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone

Prospective, Randomized, Controlled Trial of Preoperative Use of Saxenda (Liraglutide) Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

0

Recruiting sites

—

Enrollment

72

estimated

Study population

Bariatric Surgery Candidate, Obesity / overweight

Key I/E criterion

•BMI ≥35

Primary endpoint

•Body weight, % change

Identifiers

Registered as

NCT IDNCT06865365
Org study ID2493/2024

Timeline

Milestones

Study first posted2025-03-07actual
Last update posted2025-03-21actual
Study start2025-05-01estimated
Primary completion2027-02-01estimated
Study completion2028-02-01estimated

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Bariatric Surgery CandidateObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

- Patients seeking bariatric surgery

•BMI > 35.0 kg/m2
•Health insurance via Österreichische Gesundheitskasse
•Willingness to be assigned to either of the two groups
•Willingness to adhere to preoperative dietological measures
•Follow-up anticipation with blood draws and body weight scans using Secca scale
•Written informed consent

Exclusion criteria

•Patients with previous bariatric surgerys
–Patients aged below 18 years
–Patients with BMI < 35 kg/m2
–Patients with psychiatric disorders
–Patients not willing to adhere to preoperative dietological measures
–Patients with contraindications against Saxenda
–Patients who have health insurance other than Österreichische Gesundheitskasse

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
2
Glycemic / diabetes
1
Other clinical outcomes
1

Weight & body composition

2 endpoints
Primary/protocol endpoint

% total weight loss

Time frame:body weight and bmi will be assessed immediately when admission to the study is done as reference value and at at time of operation, which is 6 months after admission to the study, as outcome value

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

% weight lost after one year

Time frame:Body weight will be assessed immediately when admission to the study is done and the time of the surgery (=6 months after admission) and 1 year post op (=18 months after admission)

Body weight, % change

percent change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

hba1c

Time frame:The secondary parameters will be assessed immediately when admission to the study is done for reference and the time of the surgery, which is 6 months after admission, as outcome parameter

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint/low confidence

comorbidities

Time frame:The secondary parameters will be assessed immediately at the time when admission to the study is done for reference and the time of the surgery, which is 6 months after admission, as outcome parameter

categorical status, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.